Adverse events among chronic myelogenous leukemia patients treated with tyrosine kinase inhibitors: a real-world analysis of health plan enrollees

With tyrosine kinase inhibitor (TKI) therapy, chronic myelogenous leukemia (CML) is now a chronic disease. CML patients treated with TKIs (n=1,200) were identified from the OptumLabs(®) Data Warehouse (de-identified claims and electronic health records) between 2000-2016 and compared with a non-canc...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Leuk Lymphoma
Главные авторы: Chow, Eric J., Doody, David R., Wilkes, Jennifer J., Becker, Laura K., Chennupati, Shasank, Morin, Pamela E., Winestone, Lena E., Henk, Henry J., Lyman, Gary H.
Формат: Artigo
Язык:Inglês
Опубликовано: 2020
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC8106632/
https://ncbi.nlm.nih.gov/pubmed/33283555
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/10428194.2020.1855340
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы